Skip to main content
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · TARS ISIN · US87650L1035 US Manufacturing
Filings indexed 576 across all filing types
Latest filing 2023-05-17 Regulatory Filings
Country US United States of America
Listing US TARS

About Tarsus Pharmaceuticals, Inc.

https://www.tarsusrx.com/

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for diseases with limited treatment options. The company's initial focus is on eye care. Its lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is the first and only FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a pipeline of potential treatments for other conditions with high unmet needs, including ocular rosacea, Lyme disease prevention, and other indications across dermatology and infectious diseases.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings
2023-05-17 English
FORM 4 SUBMISSION
Director's Dealing
2023-05-15 English
FORM 4
Director's Dealing
2023-05-12 English
Regulatory Filings 2023
Regulatory Filings
2023-05-10 English
10-Q
Interim / Quarterly Report Q1 2023
2023-05-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2023, reporting the company's results of operations for the quarter ended March 31, 2023. It references a press release attached as Exhibit 99.1 that contains the financial results. The text explicitly states that the information is being furnished under Item 2.02 (Results of Operations and Financial Condition) and that the press release is incorporated by reference. The document itself is relatively short (3627 characters) and primarily serves to announce the earnings release rather than provide detailed financial statements or analysis. According to the rules, such a document is classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results with key highlights, not a full interim report or annual report. Therefore, the correct classification is ER with high confidence.
2023-05-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.